This clinical guide provides clear, plain-language, and evidence-ranked information for individuals managing lower extremity swelling, pain, and varicose veins, while equipping healthcare professionals with a rigorous diagnostic and therapeutic framework to optimize wound healing and restore standard lower extremity venous hemodynamics.
This clinical screening checklist is designed to identify high-risk scenarios requiring immediate intervention or expedited clinical routing:
The lower limb venous network consists of three distinct systems: the superficial system (Great Saphenous Vein [GSV] and Small Saphenous Vein [SSV]), the deep system (femoral, popliteal, and tibial veins), and the perforating system which penetrates the deep fascia to connect the superficial and deep networks [6:2].
The core pathology of Chronic Venous Disease (CVD) is ambulatory venous hypertension [11]. In healthy individuals, the contraction of the calf muscle pump compresses deep veins, forcing blood back to the heart, while competent bicuspid venous valves prevent retrograde flow (reflux). Valvular incompetence in the axial or perforator veins allows blood to flow retrograde, resulting in venous blood pooling, vessel dilatation, and elevated pressure during ambulation [11:1][12].
Chronic venous hypertension and altered wall shear stress initiate an inflammatory cascade within the venous endothelium, resulting in valve pathologic changes and leukocyte infiltration and activation [11:2]. The specific recruitment pathways, including endothelial adhesion molecule expression, are established by standard pathophysiological consensus. This cellular and inflammatory response is associated with elevated pro-inflammatory cytokines in ulcer tissue [13], lipodermatosclerosis secondary to chronic venous disease [14], and eventual venous ulceration [15]. Other intermediate physiological steps—including the release of matrix-degrading factors, weakening of the vein wall, and dermal remodeling—are guided by standard pathophysiological consensus.
Obesity represents a critical mechanical cofactor in CVD pathophysiology. It is an important risk factor for all types of lower limb venous disease, and obese patients are more likely to be symptomatic [16].
Accurate clinical differentiation of lower limb swelling and discomfort is crucial to prevent inappropriate interventions:
| Diagnostic Entity | Onset & Symmetry | Clinical Presentation & Skin Changes | Vascular Pulses | Ulcer Characteristics | Diagnostic Standard |
|---|---|---|---|---|---|
| Chronic Venous Disease (CVD) | Chronic; bilateral or asymmetric presentation is recognized by standard clinical consensus, with lower limb history and physical examination guidelines detailed in [6:3]. | Dull aching, heaviness, paresthesia, and pruritus [17]. Skin changes, eczema, and stasis dermatitis [18], along with pigmentation and lipodermatosclerosis [19][14:1], represent advanced manifestations of chronic venous disease. | Standard, palpable unless obscured by severe edema. | Lower extremity skin ulcers of venous origin [20]. | Duplex Ultrasound (DUS) [7:1]. |
| Deep Vein Thrombosis (DVT) | Acute (hours to days); strictly unilateral. | Severe localized calf pain, swelling, erythema, localized warmth, positive Wells score. | Standard, palpable. | N/A | Clinical prediction rules (such as the Wells score) combined with objective diagnostic imaging [1:2]. |
| Peripheral Arterial Disease (PAD) | Chronic; bilateral but asymmetric. | Intermittent claudication, rest pain relieved by dependency (based on standard clinical consensus). Thin, shiny, hairless skin, pallor on elevation, dependent rubor. | Decreased, absent, or asymmetric. | Punched-out, deep, located on toes/heels; painful; necrotic base. | Ankle-Brachial Index (ABI) assessment; Arterial Duplex. |
| Systemic Failure (Heart/Kidney) | Subacute to chronic; symmetric and bilateral. | Painless, soft pitting edema extending up the limbs. Dyspnea, orthopnea, elevated jugular venous pressure, or systemic fluid retention. | Standard, palpable. | N/A | Echocardiogram, Serum BNP, Creatinine, GFR. |
| Lymphedema | Chronic; asymmetric or unilateral. | Painless, firm non-pitting edema. Hump-like swelling respecting the foot dorsum. Positive Stemmer's sign (inability to pinch second toe skin). | Standard, palpable. | N/A | Clinical exam; Lymphoscintigraphy. |
The Clinical, Etiological, Anatomical, and Pathophysiological (CEAP) classification scheme is recommended by clinical practice guidelines to standardize the clinical routing of CVD patients [6:4][7:2]. Because the brief evidence excerpts of these guidelines do not detail the individual definitions, the mapping of clinical findings to specific CEAP stages is guided by standard clinical consensus:
s and a denote symptomatic and asymptomatic status (e.g., C2s, C4b_a).Duplex ultrasound is the undisputed gold standard for assessing venous hemodynamics and mapping reflux [6:5][7:4]. Venous incompetence is characterized by the presence of retrograde flow (reflux) [18:2]:
| Intervention | Evidence Level / GRADE | What to do | Clinical Notes & Outcomes |
|---|---|---|---|
| Compression (Active Leg Ulcers) | Moderate | Apply multi-component elastic compression (e.g., four-layer or two-layer systems) for active venous leg ulcers (C6) [6:8][22]. | High-compression multi-component systems containing elastic components significantly accelerate wound healing compared to no compression or single-component inelastic systems [22:1][20:2]. |
| Endovenous Thermal Ablation (EVTA) | High (GRADE 1B) | Route patients with great saphenous vein (GSV) incompetence to Endovenous Laser Ablation (EVLA) or Radiofrequency Ablation (RFA) [6:9][10:1]. | EVTA has replaced open surgery as first-line therapy. Demonstrates equivalent long-term occlusion (94–96% at 1 year) but significantly reduces post-operative pain and accelerates return to daily function [10:2][23][24]. |
| Micronized Purified Flavonoid Fraction (MPFF / Daflon®) | High (GRADE Moderate-to-High) | Prescribe MPFF (1000 mg daily) as an oral vasoactive agent for subjective symptoms (pain, heaviness, cramps) across all CEAP stages (C0s–C6) [17:1][25]. | High-quality trials prove MPFF reduces ankle circumference, alleviates venous symptoms, improves quality of life, and acts as an effective clinical adjunct to accelerate ulcer healing [17:2][11:3]. |
| Post-Interventional Compression | Low (GRADE 2 / Level of Evidence C) | Maintain compression therapy with GECS following thermal ablation [26][27]. | Post-procedural compression significantly decreases pain in the first 10 days post-EVTA and reduces time to return to normal activities, although it does not show a significant difference in bruising scores or long-term vein occlusion rates compared to no compression [26:1]. |
| Cyanoacrylate Glue Closure (CAC / VenaSeal) | Moderate (GRADE 2B) | Utilize CAC as a non-thermal, non-tumescent superficial vein closure technique [28][29]. | Eliminates the need for multiple tumescent local anesthetic injections and avoids risk of thermal nerve injury. Highest probability of 6-month anatomic success and minimal early post-operative pain [7:6][29:1]. |
| Graduated Compression Stockings (GECS) | Moderate (GRADE 2C) | Prescribe Class II graduated compression stockings daily (20–30 mmHg) for symptomatic varicose veins (C2) or venous edema (C3) [6:10][30]. | Reduces lower leg volume and subjective complaints of aching and tension. Arterial screening via Ankle-Brachial Index is mandatory prior to compression: standard compression is contraindicated if ABI < 0.5, and requires modified/light compression or vascular specialist consultation if ABI is between 0.5 and 0.8 [8:1][9:1][31][27:1][3:1]. |
| Superficial Surgery (HL/S & CHIVA) | Moderate (GRADE 1B / 2C) | Perform superficial surgery (such as high ligation and stripping, or CHIVA) when endovenous methods are contraindicated or unavailable [6:11][32]. | Surgical high ligation and stripping (HL/S) provides durable long-term closure but is associated with higher early hematoma rates, pain, and longer recovery [7:7][33]. CHIVA is a valve-preserving hemodynamic option that reduces side effects but is technically demanding [32:1]. |
| Sclerotherapy (UGFS or Liquid) | Low-to-Moderate (GRADE 1B/2C) | Utilize liquid sclerotherapy for C1 telangiectasias; restrict ultrasound-guided foam sclerotherapy (UGFS) to varicose tributaries or tortuous saphenous trunks [6:12][19:2]. | High-density foam sclerotherapy provides immediate cosmetic improvement and symptom relief but is associated with higher anatomical recanalization and recurrence rates compared to EVTA or surgery [7:8][10:3]. |
| Oral Vasoactive Therapy & Safety Limits | Moderate (GRADE 2C) | Utilize MPFF as the primary vetted conservative oral vasoactive agent [17:3]. | MPFF reduces microvascular permeability and fragility, increases venous tone, and attenuates hypoxia-induced endothelial inflammatory responses to relieve localized symptoms (such as pain, edema, and heaviness) [17:4]. While this localized therapy addresses microvascular tone, chronic venous disease is independently linked to elevated systemic cardiovascular risk [34]. |
| Pregnancy Guidelines | Moderate (GRADE 2C / Consensus) | Manage gestational varicose veins conservatively by avoiding invasive interventional procedures during pregnancy and expecting natural postpartum resolution. Safe, conservative lifestyle adjustments supported by clinical studies include resting in the left lateral position and wearing compression stockings [35]. Detailed lifestyle and physical protocols—such as left lateral decubitus positioning, regular leg elevation, and the use of Class I/II GECS—are supported by standard clinical consensus. | Gestational varicose veins should be managed conservatively, avoiding invasive interventional procedures during pregnancy, and expecting natural postpartum resolution. Reflexology or water immersion can reduce acute leg edema [35:1]. |
| Leg Elevation Protocols | Low (GRADE Consensus) | While leg elevation is supported as an effective treatment [15:1], the specific protocol of elevating the lower extremities above heart level for 20–30 minutes, 3–4 times daily is based on standard clinical consensus. | Mechanically lowers venous hydrostatic pressure and promotes passive gravitational drainage of pooled interstitial fluid. |
| Calf Muscle Pump Exercise | Low (GRADE Consensus) | Focus on calf muscle pump activation, structured walking, and avoiding static sitting/standing (based on standard clinical consensus). | Activates the musculovenous pump of the lower calf, decreasing ambulatory venous pressure and augmenting venous return. |
| Skin & Wound Care | Low (GRADE Consensus) | Manage active venous ulcers with standard clinical wound dressings [15:2]. The choice of specific wound care products, including the application of bland petrolatum-based emollients for stasis dermatitis (while avoiding contact sensitizers like neomycin or lanolin) and the use of advanced moisture-retentive dressings (such as hydrocolloids or foams) for active venous ulcers, is guided by standard clinical and wound care consensus. | Clinical guidelines highlight that basic dressings remain a matter of convenience, cost, and physician judgment [15:3], while specific selections of advanced moisture-retentive dressings and bland protective emollients are supported by standard clinical consensus. |
| Weight Management | Low (GRADE Consensus) | Encourage weight loss strategies for overweight and obese patients with chronic venous disease [16:1]. | Obesity is an important risk factor for lower extremity venous disease and exacerbates symptoms [16:2]. The physiological hypothesis that weight loss reduces intra-abdominal pressure and systemic inflammatory tone—which are proposed mechanical and metabolic cofactors in venous disease—is based on standard pathophysiological consensus rather than direct clinical trial evidence in lower limb venous disease. |
| Balneotherapy | Very Low to Low (GRADE 2C) | Advise mineral water immersion or spa therapy as a supportive adjunct [36]. | Provides mild, short-term relief of pain and edema through hydrostatic pressure and thermal effects [36:1]. |
The following table synthesizes key clinical evidence and statistical outcomes for primary chronic venous disease interventions:
| Intervention | Primary Clinical Outcome | GRADE Evidence Strength | Key Human Data & Statistics | Citation |
|---|---|---|---|---|
| Multi-component Compression vs. No Compression | Complete wound healing of venous leg ulcers (C6) | Moderate | Pooled hazard ratio for complete healing = 2.17 (95% CI: 1.52 to 3.10) | Shi et al. 2021 [20:3] |
| Endovenous Thermal Ablation (RFA/EVLA) vs. Open Surgical Stripping (HL/S) | Long-term anatomical GSV closure and recurrence | High | High long-term closure with no difference in 5-year recurrence rates [37]; 1-year GSV occlusion rates range between 94% and 96% [24:1] | Kheirelseid et al. 2018 [37:1]; Kempeneers et al. 2022 [24:2] |
| RFA vs. EVLA (Post-operative Recovery) | Reduced post-procedural pain | Moderate | RFA associated with significantly lower pain scores over 10 days (mean pain difference -0.85, 95% CI: -1.06 to -0.64) | Jiang et al. 2024 [38] |
| Cyanoacrylate Closure (CAC / VenaSeal) vs. EVLA/RFA | Anatomic success and adverse events | Moderate | CAC has highest probability of 6-month complete closure (rank P = 0.98); 3.3x lower adverse events than sclerotherapy | Kolluri et al. 2020 [29:2] |
| Micronized Purified Flavonoid Fraction (MPFF / Daflon®) | Reduction of pain, heaviness, and cramps | High | Reduced pain (RR 0.53, NNT = 4.2), heaviness (RR 0.35, NNT = 2.0), cramps (RR 0.51, NNT = 4.8) | Kakkos et al. 2018 [17:5] |
| Concomitant Truncal + Perforator Surgery vs. Truncal Alone | Ulcer recurrence rate at 12 months | Moderate | Significant reduction in recurrence (3.7% in concomitant vs 44% in standard surgery, RR 0.21, 95% CI: 0.07 to 0.65) | Kiernan et al. 2023 [39] |
| Oral Rutoside in Pregnancy | Symptom reduction in late pregnancy | Moderate | Significant symptom reduction in late pregnancy (RR 1.89, 95% CI: 1.11 to 3.22) | Smyth et al. 2015 [35:2] |
| Adjuvant Aspirin (300 mg daily) + Compression | Accelerated healing of chronic venous leg ulcers | Moderate | ASPiVLU trial showed no statistically significant difference in complete healing at 12 weeks | Weller et al. 2021 [40] |
Compression therapy counteracts hydrostatic venous pressure, reduces microvascular filtration, promotes lymphatic clearance, and resolves chronic lower extremity edema [30:1].
Compression therapy must never be initiated without first evaluating the arterial circulation to rule out Peripheral Arterial Disease (PAD). A thorough arterial-sufficiency assessment (ABI check) is required prior to compression when clinically indicated (such as a history of smoking, diabetes, advanced age, or diminished pulses). Clinical screening guidelines recommend performing an Ankle-Brachial Index (ABI) or ankle-brachial pressure ratio assessment to rule out significant arterial disease before any compression therapy is applied [8:2][9:2].
Consists of Endovenous Laser Ablation (EVLA) and Radiofrequency Ablation (RFA) [6:15].
Consists of Cyanoacrylate Closure (CAC / VenaSeal) and Mechanochemical Ablation (MOCA / ClariVein) [28:1][42].
Recurrent varicose veins after surgery or endovenous ablation remain a clinical challenge [46].
There is significant historical variation in compression protocols following ablation [47]. However, prospective clinical data show that post-procedural compression significantly decreases pain in the first 10 days post-EVTA and reduces time to return to normal activities, although it does not show a significant difference in bruising scores or long-term vein occlusion rates compared to no compression [26:2].
Pregnancy is a major physiologic risk factor for temporary or permanent varicose veins and lower extremity edema, driven by elevated progesterone (which relaxes vascular smooth muscle), increased blood volume, and mechanical compression of the inferior vena cava by the gravid uterus [35:3]. Gestational varicose veins should be managed conservatively, avoiding invasive interventional procedures during pregnancy, and expecting natural postpartum resolution.
Vasoactive therapy, including Micronized Purified Flavonoid Fraction (MPFF), Aescin (horse chestnut seed extract), and Butcher's Broom (Ruscus aculeatus), is utilized to support microvascular filtration and venous wall tone to relieve localized symptoms like pain, edema, and heaviness [17:6][25:1]. However, clinicians must clarify that while these agents support microvascular filtration and venous wall tone to relieve localized symptoms, they do not prevent cardiovascular events or mitigate systemic arterial/atherothrombotic risk. Other oral supplements, such as horse chestnut seed extract (Aescin), Butcher's Broom, and hydroxyethylrutosides, are often less supported by our primary clinical practice guidelines due to limited or inconsistent evidence, leaving MPFF as the fully vetted and supported first-line oral vasoactive treatment.
Clinicians must clarify to patients that while oral vasoactive therapies (such as MPFF, Aescin, or Butcher's Broom) are highly effective at supporting microvascular filtration and venous wall tone to relieve localized symptoms (such as pain, edema, and heaviness) [17:9], they do not prevent cardiovascular events or mitigate systemic arterial/atherothrombotic risk. Chronic venous disease itself is independently associated with an increased risk of coronary artery disease, stroke, peripheral arterial disease, and cardiovascular mortality [34:1]. While phlebotonics treat localized venous pathophysiology, they do not mitigate systemic arterial or atherothrombotic risk, meaning that comprehensive cardiovascular risk assessment remains essential in these patients [34:2].
Vasoactive supplements like MPFF, Aescin, or Butcher's Broom do not address systemic arterial or cardiovascular risk. For screening of systemic atherosclerosis, coronary artery calcium scoring, and peripheral vascular health, refer to the Coronary Artery Calcium Scoring, Arterial Stiffness and Pulse-Wave Velocity, and Ankle-Brachial Index and Peripheral Artery Disease Screening guides.
Vascular specialists and primary care clinicians should screen for the following clinical indicators to guide treatment escalation or emergency referral:
To expand your vascular screening and assessment capabilities, refer to the Ankle-Brachial Index and Peripheral Artery Disease Screening guide.
Longevipedia pages are AI-updated and human-reviewed. We prioritize high-certainty human clinical evidence, systematically cite peer-reviewed literature, and update clinical monographs when consensus or clinical guidelines evolve.
Bauersachs RM. Clinical presentation of deep vein thrombosis and pulmonary embolism. Best Pract Res Clin Haematol. 2012;25(3):243-251. doi:10.1016/j.beha.2012.07.004. https://pubmed.ncbi.nlm.nih.gov/22959541/ ↩︎ ↩︎ ↩︎ ↩︎
Rayala BZ. Skin Ulcers: Prevention and Diagnosis of Pressure, Venous Leg, and Arterial Ulcers. FP Essent. 2020;499:21-25. https://pubmed.ncbi.nlm.nih.gov/33263972/ ↩︎
Tickle J, Robinson H, Stubbings W, et al. A reduced multicomponent bandage compression system in the management of venous leg ulcers: a clinical evaluation. J Wound Care. 2025;34(11):S1-S8. https://pubmed.ncbi.nlm.nih.gov/41201874/ ↩︎ ↩︎ ↩︎
Ahmed A, Naeem N, Jain A, et al. Acute Limb Ischemia Interventions. Interv Cardiol Clin. 2025;14(2):189-201. doi:10.1016/j.iccl.2024.11.012. https://pubmed.ncbi.nlm.nih.gov/40049853/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Steurer J, Schneider E. [The diagnosis of peripheral arterial embolism]. Herz. 1991;16(6):363-368. https://pubmed.ncbi.nlm.nih.gov/1765345/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Gloviczki P, Comerota AJ, Dalsing MC, et al. The care of patients with varicose veins and associated chronic venous diseases: clinical practice guidelines of the Society for Vascular Surgery and the American Venous Forum. J Vasc Surg. 2011;53(5 Suppl):16S-48S. https://pubmed.ncbi.nlm.nih.gov/21536172/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Farah MH, Nayfeh T, Urtecho M, et al. A systematic review supporting the Society for Vascular Surgery, the American Venous Forum, and the American Vein and Lymphatic Society guidelines on the management of varicose veins. J Vasc Surg Venous Lymphat Disord. 2022;10(5):1155-1171. https://pubmed.ncbi.nlm.nih.gov/34450355/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
de Carvalho MR, de Andrade IS, de Abreu AM, et al. All about compression: A literature review. J Vasc Nurs. 2016;34(2):39-44. https://pubmed.ncbi.nlm.nih.gov/27210451/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Weller CD, Team V, Ivory JD, et al. ABPI reporting and compression recommendations in global clinical practice guidelines on venous leg ulcer management: A scoping review. Int Wound J. 2019;16(2):405-415. https://pubmed.ncbi.nlm.nih.gov/30485668/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Rasmussen LH, Lawaetz M, Bjoern L, et al. Randomized clinical trial comparing endovenous laser ablation, radiofrequency ablation, foam sclerotherapy and surgical stripping for great saphenous varicose veins. Br J Surg. 2011;98(8):1079-1087. https://pubmed.ncbi.nlm.nih.gov/21725957/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Bergan JJ. Chronic venous insufficiency and the therapeutic effects of Daflon 500 mg. Angiology. 2005;56(Suppl 1):S9-18. https://pubmed.ncbi.nlm.nih.gov/16193222/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Tan MKH, Bootun R, Wang R, et al. A systematic review of anatomical reflux patterns in primary chronic venous disease. J Vasc Surg Venous Lymphat Disord. 2024;12(6):102604. https://pubmed.ncbi.nlm.nih.gov/39025298/ ↩︎
Beidler SK, Douillet CD, Berndt DF, et al. Inflammatory cytokine levels in chronic venous insufficiency ulcer tissue before and after compression therapy. J Vasc Surg. 2009;49(4):1013-1020. doi:10.1016/j.jvs.2008.11.007. https://pubmed.ncbi.nlm.nih.gov/19341889/ ↩︎
Arendsen LP, Vig S, Thakar R. Impact of copper compression stockings on venous insufficiency and lipodermatosclerosis: A randomised controlled trial. Phlebology. 2019;34(4):230-237. https://pubmed.ncbi.nlm.nih.gov/30149775/ ↩︎ ↩︎ ↩︎
Alguire PC, Mathes BM. Chronic venous insufficiency and venous ulceration. J Gen Intern Med. 1997;12(6):374-383. https://pubmed.ncbi.nlm.nih.gov/9192256/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Davies HO, Popplewell M, Singhal R. Obesity and lower limb venous disease - The epidemic of phlebesity. Phlebology. 2017;32(4):227-233. https://pubmed.ncbi.nlm.nih.gov/27178403/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Kakkos SK, Nicolaides AN. Efficacy of micronized purified flavonoid fraction (Daflon®) on improving individual symptoms, signs and quality of life in patients with chronic venous disease: a systematic review and meta-analysis of randomized double-blind placebo-controlled trials. Int Angiol. 2018;37(2):143-154. https://pubmed.ncbi.nlm.nih.gov/29385792/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Gracia S, Miserey G, Risse J, et al. Update of the SFMV (French society of vascular medicine) guidelines on the conditions and safety measures necessary for thermal ablation of the saphenous veins and proposals for unresolved issues. J Med Vasc. 2020;45(3):148-158. https://pubmed.ncbi.nlm.nih.gov/32402427/ ↩︎ ↩︎ ↩︎ ↩︎
de Ávila Oliveira R, Riera R, Vasconcelos V. Injection sclerotherapy for varicose veins. Cochrane Database Syst Rev. 2021;12(12):CD010185. https://pubmed.ncbi.nlm.nih.gov/34883526/ ↩︎ ↩︎ ↩︎ ↩︎
Shi C, Dumville JC, Cullum N, et al. Compression bandages or stockings versus no compression for treating venous leg ulcers. Cochrane Database Syst Rev. 2021;7(7):CD013397. https://pubmed.ncbi.nlm.nih.gov/34308565/ ↩︎ ↩︎ ↩︎ ↩︎
Bayer A, Kuznik N, Langan EA, et al. Clinical outcome of short-term compression after sclerotherapy for telangiectatic varicose veins. J Vasc Surg Venous Lymphat Disord. 2021;9(2):397-404. https://pubmed.ncbi.nlm.nih.gov/32502730/ ↩︎ ↩︎ ↩︎
O'Meara S, Cullum N, Nelson EA, et al. Compression for venous leg ulcers. Cochrane Database Syst Rev. 2012;11(11):CD000265. https://pubmed.ncbi.nlm.nih.gov/23152202/ ↩︎ ↩︎
Shepherd AC, Gohel MS, Brown LC, et al. Randomized clinical trial of VNUS ClosureFAST radiofrequency ablation versus laser for varicose veins. Br J Surg. 2010;97(6):810-818. https://pubmed.ncbi.nlm.nih.gov/20473992/ ↩︎ ↩︎
Kempeneers AC, Bechter-Hugl B, Thomis S, et al. A prospective multicenter randomized clinical trial comparing endovenous laser ablation, using a 1470 nm diode laser in combination with a Tulip-TipTM fiber versus radiofrequency (Closure FAST™ VNUS®), in the treatment of primary varicose veins. Int Angiol. 2022;41(4):320-327. https://pubmed.ncbi.nlm.nih.gov/35166103/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Eliete B, Igor Z, Miguel A. Effectiveness of micronized purified flavonoid fraction in early stage chronic venous disease-Clinical, Etiological, Anatomical, and Pathophysiological C0s-C1: A systematic review and meta-analysis. J Vasc Surg Venous Lymphat Disord. 2026. https://pubmed.ncbi.nlm.nih.gov/42331095/ ↩︎ ↩︎ ↩︎
Ma F, Xu H, Zhang J, et al. Compression Therapy Following Endovenous Thermal Ablation of Varicose Veins: A Systematic Review and Meta-Analysis. Ann Vasc Surg. 2022;80:317-325. https://pubmed.ncbi.nlm.nih.gov/34774690/ ↩︎ ↩︎ ↩︎
Lurie F, Lal BK, Antignani PL, et al. Compression therapy after invasive treatment of superficial veins of the lower extremities: Clinical practice guidelines of the American Venous Forum, Society for Vascular Surgery, American College of Phlebology, Society for Vascular Medicine, and International Union of Phlebology. J Vasc Surg Venous Lymphat Disord. 2019;7(1):17-28. https://pubmed.ncbi.nlm.nih.gov/30554745/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Gloviczki P, Lawrence PF, Wasan SM, et al. The 2023 Society for Vascular Surgery, American Venous Forum, and American Vein and Lymphatic Society clinical practice guidelines for the management of varicose veins of the lower extremities. Part II: Endorsed by the Society of Interventional Radiology and the Society for Vascular Medicine. J Vasc Surg Venous Lymphat Disord. 2024;12(1):101670. https://pubmed.ncbi.nlm.nih.gov/37652254/ ↩︎ ↩︎
Kolluri R, Chung J, Kim S. Network meta-analysis to compare VenaSeal with other superficial venous therapies for chronic venous insufficiency. J Vasc Surg Venous Lymphat Disord. 2020;8(3):447-455. https://pubmed.ncbi.nlm.nih.gov/32063522/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Häfner HM, Eichner M, Jünger M. [Medical compression therapy]. Zentralbl Chir. 2001;126(7):527-531. https://pubmed.ncbi.nlm.nih.gov/11503471/ ↩︎ ↩︎ ↩︎ ↩︎
Andriessen A, Apelqvist J, Mosti G, et al. Compression therapy for venous leg ulcers: risk factors for adverse events and complications, contraindications - a review of present guidelines. J Eur Acad Dermatol Venereol. 2017;31(9):1503-1508. https://pubmed.ncbi.nlm.nih.gov/28602045/ ↩︎ ↩︎ ↩︎
Bellmunt-Montoya S, Escribano JM, Dilme J, et al. CHIVA method for the treatment of chronic venous insufficiency. Cochrane Database Syst Rev. 2015;6(6):CD009648. https://pubmed.ncbi.nlm.nih.gov/26121003/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Siribumrungwong B, Noorit P, Wilasrusmee C, et al. A systematic review and meta-analysis of randomised controlled trials comparing endovenous ablation and surgical intervention in patients with varicose vein. Eur J Vasc Endovasc Surg. 2012;44(2):214-223. https://pubmed.ncbi.nlm.nih.gov/22705163/ ↩︎ ↩︎
Del Río-Solá ML, Cenizo-Revuelta N, Saiz Viloria L. The cardiovascular impact of chronic venous disease: A systematic review and meta-analysis. J Vasc Surg Venous Lymphat Disord. 2026. https://pubmed.ncbi.nlm.nih.gov/40912305/ ↩︎ ↩︎ ↩︎
Smyth RM, Aflaifel N, Bamigboye AA. Interventions for varicose veins and leg oedema in pregnancy. Cochrane Database Syst Rev. 2015;(10):CD001066. https://pubmed.ncbi.nlm.nih.gov/26477632/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
de Moraes Silva MA, Nakano LC, Cisneros LL, et al. Balneotherapy for chronic venous insufficiency. Cochrane Database Syst Rev. 2023;1(1):CD010086. https://pubmed.ncbi.nlm.nih.gov/36622745/ ↩︎ ↩︎
Kheirelseid EAH, Crowe G, Sehgal R, et al. Systematic review and meta-analysis of randomized controlled trials evaluating long-term outcomes of endovenous management of lower extremity varicose veins. J Vasc Surg Venous Lymphat Disord. 2018;6(2):258-270. https://pubmed.ncbi.nlm.nih.gov/29292115/ ↩︎ ↩︎
Jiang W, Liang Y, Long Z. Endovenous radiofrequency ablation vs laser ablation in patients with lower extremity varicose veins: A meta-analysis. J Vasc Surg Venous Lymphat Disord. 2024;12(5):102434. https://pubmed.ncbi.nlm.nih.gov/38316290/ ↩︎ ↩︎
Kiernan A, Fahey B, Boland F, et al. A systematic review and meta-analysis of concomitant truncal and perforator surgery. J Vasc Surg Venous Lymphat Disord. 2023;11(3):645-654. https://pubmed.ncbi.nlm.nih.gov/36736858/ ↩︎
Weller CD, Martin C, Bouguettaya A, et al. Once daily 300 mg aspirin with compression versus compression alone in patients with chronic venous leg ulcers (ASPiVLU): A randomised, double-blinded, multicentre, placebo-controlled, clinical trial. J Tissue Viability. 2021;30(4):501-508. https://pubmed.ncbi.nlm.nih.gov/34330595/ ↩︎
Azirar S, Appelen D, Prins MH. Compression therapy for treating post-thrombotic syndrome. Cochrane Database Syst Rev. 2019;9(9):CD004177. https://pubmed.ncbi.nlm.nih.gov/31531971/ ↩︎
Vähäaho S, Mahmoud O, Halmesmäki K, et al. Randomized clinical trial of mechanochemical and endovenous thermal ablation of great saphenous varicose veins. Br J Surg. 2019;106(5):548-554. https://pubmed.ncbi.nlm.nih.gov/30908611/ ↩︎ ↩︎ ↩︎
Chaitidis N, Kokkinidis DG, Papadopoulou Z, et al. Treatment of chronic venous disorder: A comprehensive review. Dermatol Ther. 2022;35(2):e15241. https://pubmed.ncbi.nlm.nih.gov/34859549/ ↩︎ ↩︎
Paravastu SC, Horne M, Dodd PD. Endovenous ablation therapy (laser or radiofrequency) or foam sclerotherapy versus conventional surgical repair for short saphenous varicose veins. Cochrane Database Syst Rev. 2016;11(11):CD010814. https://pubmed.ncbi.nlm.nih.gov/27898181/ ↩︎
Winterborn RJ, Earnshaw JJ. Crossectomy and great saphenous vein stripping. J Cardiovasc Surg (Torino). 2006;47(1):19-25. https://pubmed.ncbi.nlm.nih.gov/16434942/ ↩︎ ↩︎
O'Donnell TF, Balk EM, Dermody M, et al. Recurrence of varicose veins after endovenous ablation of the great saphenous vein in randomized trials. J Vasc Surg Venous Lymphat Disord. 2016;4(1):97-105. https://pubmed.ncbi.nlm.nih.gov/26946904/ ↩︎ ↩︎ ↩︎
El-Sheikha J, Carradice D, Nandhra S. A systematic review of the compression regimes used in randomised clinical trials following endovenous ablation. Phlebology. 2017;32(4):259-267. https://pubmed.ncbi.nlm.nih.gov/27178404/ ↩︎